Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(98)00249-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.
Viruses
December 2024
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality. Treatment can be challenging due to medication-associated toxicities. Maribavir (MBV) is a promising option for the treatment of resistant or refractory (R/R) CMV infection in lieu of foscarnet (FOS), which has long been the recommended therapy for (val)ganciclovir-resistant infection.
View Article and Find Full Text PDFEffectiveness of complement inhibitors against refractory antibody-mediated rejection of lung transplantation: Two clinical cases.
Transpl Immunol
January 2025
Univ. Grenoble Alpes, CNRS, Pharmacy Department, TIMC, UMR5525, Grenoble Alpes University, Grenoble, France.
Antibody-mediated rejection (AMR) has been recognized as a significant cause of acute and chronic lung allograft dysfunction after lung transplantation. Some treatments, eculizumab, an anti-complement (C)5 component monoclonal antibody (Mab), seem to have a promising effect in the management of some patients with AMR. We present two patients with acute AMR after lung transplantation who received the anti-C5 Mab therapy.
View Article and Find Full Text PDFSuccessful Management of Refractory Cytomegalovirus Infection After Intestinal Transplantation Using Maribavir.
Transpl Infect Dis
December 2024
Department of Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan.
Contribution of long-lived plasma cells to antibody-mediated allograft rejection.
Clin Transplant Res
December 2024
Laboratory of Autoimmunology, Department of Anatomy and Cell Biology, Hanyang University College of Medicine, Seoul, Korea.
Persistent alloantigens derived from allograft tissues can be recognized by the host's alloreactive immune system. This process enables cognate B cells to differentiate into plasma cells, which secrete donor-specific antibodies that are key drivers of antibody-mediated allograft rejection. A subset of these plasma cells can survive for extended periods in a suitable survival niche and mature into long-lived plasma cells (LLPCs), which are a cellular component of humoral memory.
View Article and Find Full Text PDFBisphosphonate therapy for persistent hyperparathyroidism after kidney transplantation-A case report.
Nephrology (Carlton)
January 2025
Kwong Wah Hospital, Kowloon, Hong Kong.
Post-transplant hyperparathyroidism (PT-HPT) is common in kidney transplant recipients (KTRs) and can cause nephrocalcinosis and graft dysfunction. Cinacalcet is commonly used for treating PT-HPT but may induce calciuria and exacerbate nephrocalcinosis. The concurrent use of bisphosphonates with cinacalcet to prevent this complication has not been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!